Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Long-Term Debt Repayments: 2014-2025

Historic Long-Term Debt Repayments for vTv Therapeutics (VTVT) over the last 6 years, with Sep 2025 value amounting to $64,000.

  • vTv Therapeutics' Long-Term Debt Repayments was N/A to $64,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $630,000, marking a year-over-year change of. This contributed to the annual value of $191,000 for FY2024, which is 68.11% down from last year.
  • Per vTv Therapeutics' latest filing, its Long-Term Debt Repayments stood at $64,000 for Q3 2025, which was down 66.49% from $191,000 recorded in Q1 2024.
  • In the past 5 years, vTv Therapeutics' Long-Term Debt Repayments registered a high of $380,000 during Q4 2021, and its lowest value of $64,000 during Q3 2025.
  • In the last 3 years, vTv Therapeutics' Long-Term Debt Repayments had a median value of $191,000 in 2024 and averaged $170,800.
  • As far as peak fluctuations go, vTv Therapeutics' Long-Term Debt Repayments slumped by 95.36% in 2021, and later surged by 204.76% in 2022.
  • Quarterly analysis of 5 years shows vTv Therapeutics' Long-Term Debt Repayments stood at $380,000 in 2021, then fell by 12.37% to $333,000 in 2022, then dropped by 15.32% to $282,000 in 2023, then dropped by 14.73% to $191,000 in 2024, then reached $64,000 in 2025.
  • Its Long-Term Debt Repayments was $64,000 in Q3 2025, compared to $191,000 in Q1 2024 and $282,000 in Q4 2023.